Results of the Use of Proctokinase in Acute Hemorrhoids

Abstract

Introduction: Acute hemorrhoids are the most common proctological condition and constitute a significant health problem. The use of recombinant streptokinase in the medical treatment of hemorrhoidal crisis has recently been reported.

Objective: To evaluate the results of using recombinant proctokinase suppositories in acute hemorrhoids.

Method: A prospective longitudinal study was conducted with 32 patients suffering from acute hemorrhoids treated in the coloproctology department of the Comandante Manuel Fajardo Clinical-Surgical University Hospital from January to June 2025. Patients were evaluated at the time of diagnosis and 72 hours after starting treatment with proctokinase.

Results: The predominant age group was 40-49 years (56.24%), with a male predominance. Perianal pain was the main symptom (93.75%), and edema was the predominant sign seen in 100% of patients. Hemorrhoidal thrombosis occurred in 18 patients (56.26%), with males being the most affected (59.37%). Sixty-eight-point seven six percent of patients received four doses of the proctokinase suppository, and of these, fifty-nine-point three seven percent resolved completely, while twenty-one-point eight eight percent required thrombectomy.

Conclusions: The recombinant proctokinase suppository in hemorrhoidal crisis reduces the lesion and improves edema and anal pain. The results of the research confirm that it is an effective and safe therapy, particularly for hemorrhoidal fluxion, and consolidate it as a significant advance in Cuban pharmacology.